BioMosae key facts
as of Oct 2026- Developer of metabolite-based biofungicides designed to control plant diseases through non-living microbial compounds.
- BioMosae is valued at approximately $2.5M as of Oct 2026 (last reported valuation).
- It has raised $3.7M; the latest was Later Stage VC ($4.1M) in Mar 2026.
- Notable investors include StartLife, Limburg Development and Investment Company.
- Status: Privately Held (backing).
BioMosae's last reported valuation, Sep 2022. Nothing priced has surfaced since.
- ·Watch BioMosae: the Monday email on marks, rounds and moves
BioMosae funding rounds
No funding rounds for BioMosae are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs BioMosae
2BioMosae valuation
BioMosae's last reported valuation was $2.5 million in Sep 2022. No priced round, secondary trade or fund mark has surfaced since.
BioMosae investors
2 investors are on record for BioMosae, including StartLife and Limburg Development and Investment Company.
About BioMosae
Developer of metabolite-based biofungicides designed to control plant diseases through non-living microbial compounds. The company offers biofungicides derived from naturally occurring microbial metabolites with a distinct mode of action and consistent performance, enabling agricultural producers to manage crop diseases through sustainable and non-chemical approaches.
- Sector
- Healthcare
- HQ
- Geleen, Netherlands
- Founded
- 2018
- Employees
- 5
- Website
- biomosae.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.